MX2022006674A - Composiciones de celulas t reguladoras (treg) y metodos para tratar enfermedades neurodegenerativas. - Google Patents
Composiciones de celulas t reguladoras (treg) y metodos para tratar enfermedades neurodegenerativas.Info
- Publication number
- MX2022006674A MX2022006674A MX2022006674A MX2022006674A MX2022006674A MX 2022006674 A MX2022006674 A MX 2022006674A MX 2022006674 A MX2022006674 A MX 2022006674A MX 2022006674 A MX2022006674 A MX 2022006674A MX 2022006674 A MX2022006674 A MX 2022006674A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- cells
- treg
- regulatory
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 210000003289 regulatory T cell Anatomy 0.000 title abstract 3
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 2
- 208000025966 Neurological disease Diseases 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/16—Physical preservation processes
- A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/414—Nervous system antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944346P | 2019-12-05 | 2019-12-05 | |
| PCT/US2020/063378 WO2021113685A2 (en) | 2019-12-05 | 2020-12-04 | Regulatory t cell (treg) compositions and methods for treating neurodegenerative disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006674A true MX2022006674A (es) | 2022-11-14 |
Family
ID=74104193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006674A MX2022006674A (es) | 2019-12-05 | 2020-12-04 | Composiciones de celulas t reguladoras (treg) y metodos para tratar enfermedades neurodegenerativas. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230047159A1 (enExample) |
| EP (1) | EP4069259A2 (enExample) |
| JP (1) | JP2023504734A (enExample) |
| AU (1) | AU2020397893A1 (enExample) |
| CA (1) | CA3159411A1 (enExample) |
| MX (1) | MX2022006674A (enExample) |
| WO (1) | WO2021113685A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3221900A1 (en) * | 2021-06-08 | 2022-12-15 | Stanley Hersh Appel | Methods for producing regulatory t cell (treg) populations, treg compositions and methods for treatment |
| WO2024233788A2 (en) * | 2023-05-09 | 2024-11-14 | The Mclean Hospital Corporation | Intra-striatal co-transplantation of autologous treg and mda cells in parkinson's disease cell therapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| JP5602133B2 (ja) * | 2009-04-24 | 2014-10-08 | 株式会社林原 | 細胞障害活性及び免疫抑制活性を併せ持つヒトｔ細胞集団の製造方法 |
| CN109715196A (zh) * | 2016-06-13 | 2019-05-03 | 转矩医疗股份有限公司 | 用于促进免疫细胞功能的组合物和方法 |
-
2020
- 2020-12-04 US US17/292,423 patent/US20230047159A1/en active Pending
- 2020-12-04 EP EP20830430.3A patent/EP4069259A2/en active Pending
- 2020-12-04 WO PCT/US2020/063378 patent/WO2021113685A2/en not_active Ceased
- 2020-12-04 AU AU2020397893A patent/AU2020397893A1/en active Pending
- 2020-12-04 MX MX2022006674A patent/MX2022006674A/es unknown
- 2020-12-04 CA CA3159411A patent/CA3159411A1/en active Pending
- 2020-12-04 JP JP2022534147A patent/JP2023504734A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230047159A1 (en) | 2023-02-16 |
| AU2020397893A1 (en) | 2022-06-09 |
| CA3159411A1 (en) | 2021-06-10 |
| WO2021113685A3 (en) | 2021-07-08 |
| WO2021113685A2 (en) | 2021-06-10 |
| EP4069259A2 (en) | 2022-10-12 |
| JP2023504734A (ja) | 2023-02-06 |
| AU2020397893A8 (en) | 2022-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021021979A3 (en) | Hdac6 inhibitors and uses thereof | |
| CL2018001089A1 (es) | Sales de valbenazina y polimorfos de las mismas. | |
| MX378707B (es) | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. | |
| JOP20190193A1 (ar) | ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان | |
| UY28011A1 (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| DE69942702D1 (de) | Zusammenstellungen und methoden zur behandlung der alzheimerschen krankheit, schäden des zentralnervensystems und entzündlichen erkrankungen | |
| BR112019011462A2 (pt) | peptídeo coagonista de gip/glp-1, e, peptídeo para uso no tratamento e/ou profilaxia da doença de alzheimer clínica. | |
| MX2023007998A (es) | Regimenes de tratamiento con dexmedetomidina. | |
| BRPI0712322A2 (pt) | compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos | |
| BR0312232A (pt) | Inibidores de caspases e seus usos | |
| ZA201903226B (en) | Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same | |
| MX2023003348A (es) | Compuestos y composiciones como moduladores de señalización tlr. | |
| PH12016500715A1 (en) | Di-isopropyl-phosphinoyl-alkane (dapa) compounds as topical agents for the treatment of sensory discomfort | |
| BR112021023054A2 (pt) | Formas cristalinas de um inibidor de btk | |
| EP4566629A3 (en) | Use of low volume plasma exchange for the treatment of alzheimer s disease in early and middle stages | |
| MX2022006674A (es) | Composiciones de celulas t reguladoras (treg) y metodos para tratar enfermedades neurodegenerativas. | |
| SA522433282B1 (ar) | طريقة تمييز الخلايا العصبية والتركيبات ذات الصلة وطرق استخدامها | |
| NZ755442A (en) | Topical cyclosporine-containing formulations and uses thereof | |
| PH12021550043A1 (en) | Use of riluzole prodrugs to treat alzheimer's disease | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| CR20210499A (es) | Compuestos y composiciones como moduladores de la señalización de tlr | |
| BR112019005428A2 (pt) | agentes, usos e métodos de tratamento | |
| MX2023002350A (es) | Composiciones y metodos para mejorar enfermedades y trastornos neurologicos. | |
| MX388366B (es) | Composiciones para tratar enfermedades neurodegenerativas. |